Myriad Genetics appointed Vishal Sikri as executive vice president, commercial, effective September 16, 2026, replacing Brian Donnelly, who is leaving on September 21. Donnelly will remain a non-executive employee through that date to support the transition, while the company reaffirms its full-year 2026 financial guidance.

Key Highlights

  • Vishal Sikri moved from senior vice president, product, to executive vice president, commercial, effective September 16, 2026.
  • Brian Donnelly will leave Myriad Genetics on September 21, 2026, after serving as chief commercial officer since May 2025.
  • Myriad Genetics reaffirmed its full-year 2026 financial guidance.

Myriad Genetics Inc. (NASDAQ: MYGN) appointed Vishal Sikri as executive vice president, commercial, effective September 16, 2026.

Sikri Takes Commercial Leadership Sikri previously served as

Myriad Genetics’ senior vice president, product. Donnelly is expected to remain with Myriad Genetics as a non-executive employee through September 21, 2026, to assist with the handover of his responsibilities. He had served as chief commercial officer since May 2025.

Full-Year 2026 Guidance Reaffirmed Myriad Genetics

reaffirmed its financial guidance for full-year 2026. Sikri said he was energized to lead the commercial organization and advance Myriad Genetics’ mission.